BlueCross BlueShield of Tennessee Medical Policy Manual

Microarray-based Gene Expression Testing for Cancers of Unknown Primary

Does Not Apply to Commercial Genetic Testing Program effective 6/1/2018

DESCRIPTION

Cancers of unknown primary (CUP) or occult primary malignancies are tumors that have metastasized from an unknown primary source, and make up approximately 2% - 4% of all cancer cases in the United States. These cancers are often accompanied by a poor prognosis.

Conventional methods used to aid in the identification of the origin of a cancer of unknown primary malignancy include a thorough history and physical examination, computed tomography (CT) scans of the chest, abdomen, and pelvis, routine laboratory studies, and targeted evaluation of specific signs and symptoms. Identifying the primary origin of a tumor can dictate cancer specific treatment, expected outcome, and prognosis.

Microarray-based gene expression testing, also known as gene expression profiling, is proposed for use in identifying the original site of cancers of unknown primary. These tests measure the expression of up to 2,000 genes and compare the similarity of the gene expression profile of a cancer of unknown primary to a database of known tissue profiles with histologic morphologies. Examples of these tests include Tissue of Origin®, CancerTYPE ID®, and RosettaGX Cancer Origin™.

POLICY

IMPORTANT REMINDERS

ADDITIONAL INFORMATION  

The clinical utility of microarray-based gene expression testing for cancers of unknown primary has not been determined. The clinical application of gene expression profiling to direct patient management and tumor site-specific therapy also has not been demonstrated in prospective studies. The impact of this testing on clinical outcomes remains unknown.

SOURCES 

Agency for Healthcare Research and Quality. (2013, February). Technology assessment on genetic testing or molecular pathology testing of cancers with unknown primary site to determine origin. Retrieved November 3, 2016 from http://www.ahrq.gov.

Agwa, E., & Ma, P. (2013). Overview of various techniques/platforms with critical evaluation of each. Current Treatment Options in Oncology, 14 (4), 623-633. Abstract retrieved October 13, 2017 from PubMed database.

American Cancer Society. ( 2016, January). Cancer – unknown primary. Retrieved November 3, 2016 from www.cancer.org.

BlueCross BlueShield Association. Evidence Positioning System. (4:2019). Gene expression-based assays for cancers of unknown primary (2.04.54). Retrieved October 1, 2019 from https://www.evidencepositioningsystem.com. (32 articles and/or guidelines reviewed)

Greco, F.A., Lennington, W.J., Spigel, D.R., & Hainsworth, J.D. (2015). Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. Molecular Diagnosis & Therapy, 19 (2), 91-97. Abstract retrieved September 19, 2018 from PubMed database.

National Comprehensive Cancer Network. (2019, January). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Occult primary (cancer of unknown primary, [CUP]) (V.2.2019). Retrieved October 1, 2019 from the National Comprehensive Cancer Network.

National Institute for Health and Clinical Excellence (NICE). (2010, July). Metastatic malignant disease of unknown primary origin. Retrieved February 28, 2013 from http://www.nice.org. 

Sokilde, R., Vincent, M., Moller, A., Hansen, A., Hoiby, P., Blondal, T., et al. (2014). Efficient identification of miRNAs for classification of tumor origin. The Journal of Molecular Diagnostics, 16 (1), 106-115. (Level 4 evidence)

U. S. Food and Drug Administration. (2012, May). Center for Devices and Radiological Health. 510(k) Premarket Notification Database. K120489. Retrieved February 28, 2013 from http://www.accessdata.fda.gov.

Yoon, H.H., Foster, N.R., Meyers, J.P., Steen, P.D., Visscher, D.W., Pillai, R., et al. (2015). Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Annals of Oncology, 27, 339-344. (Level 3 evidence)

ORIGINAL EFFECTIVE DATE:  11/14/2009

MOST RECENT REVIEW DATE:  11/14/2019

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.